Journal article
A CGRP receptor antagonist peptide formulated for nasal administration to treat migraine
Journal of pharmacy and pharmacology, Vol.72(10), pp.1352-1360
10/2020
DOI: 10.1111/jphp.13317
PMCID: PMC7486274
PMID: 32588458
Abstract
Objectives
To investigate the formulation of the peptide‐based antagonist (34Pro,35Phe)CGRP27–37, of the human calcitonin gene‐related peptide (CGRP) receptor as a potential nasally delivered migraine treatment.
Methods
Peptide sequences were prepared using automated methods and purified by preparative HPLC. Their structure and stability were determined by LC‐MS. Antagonist potency was assessed by measuring CGRP‐stimulated cAMP accumulation in SK‐N‐MC, cells and in CHO cells overexpressing the human CGRP receptor. In vivo activity was tested in plasma protein extravasation (PPE) studies using Evans blue dye accumulation. Peptide‐containing chitosan microparticles were prepared by spray drying.
Key findings
(34Pro,35Phe)CGRP27–37 exhibited a 10‐fold increased affinity compared to αCGRP27–37. Administration of (34Pro,35Phe)CGRP27–37 to mice led to a significant decrease in CGRP‐induced PPE confirming antagonistic properties in vivo. There was no degradation of (34Pro,35Phe)CGRP27–37 and no loss of antagonist potency during formulation and release from chitosan microparticles.
Conclusions
(34Pro,35Phe)CGRP27–37 is a potent CGRP receptor antagonist both in vitro and in vivo, and it can be formulated as a dry powder with no loss of activity indicating its potential as a nasally formulated anti‐migraine medicine.
Details
- Title: Subtitle
- A CGRP receptor antagonist peptide formulated for nasal administration to treat migraine
- Creators
- Bengt Mentzer - Innovipharm LimitedAndrew F Russo - University of IowaZhongming Zhang - Nanyang Institute of TechnologyAdisa Kuburas - University of IowaPatrick M Killoran - University of OxfordVera D’Aloisio - Liverpool John Moores UniversityLaura Nizic - University of ZagrebVicky Capel - Catalent Pharma SolutionsDavid A Kendall - Liverpool John Moores UniversityChristopher R Coxon - Heriot‐Watt UniversityGillian A Hutcheon - Liverpool John Moores University
- Resource Type
- Journal article
- Publication Details
- Journal of pharmacy and pharmacology, Vol.72(10), pp.1352-1360
- DOI
- 10.1111/jphp.13317
- PMID
- 32588458
- PMCID
- PMC7486274
- NLM abbreviation
- J Pharm Pharmacol
- ISSN
- 0022-3573
- eISSN
- 2042-7158
- Number of pages
- 9
- Grant note
- Innovate UK (Biomedical Catalyst Project) (132677) Foundation for the National Institutes of Health (NS075599)
- Language
- English
- Date published
- 10/2020
- Academic Unit
- Neurology; Molecular Physiology and Biophysics; Iowa Neuroscience Institute; Craniofacial Anomalies Research Center
- Record Identifier
- 9984070296902771
Metrics
50 Record Views